Recent studies have also shown that TKI treatment in RCC can induce PD-L1 expression and the release of soluble PD-L1 from tumor cells, thereby impairing T cell activation, reducing cytokine production, and decreasing the proportion of activated T cells[86]. Here, CD274 is linked to neoplasm.